Fresh analysis suggests that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Findings released in a major health publication demonstrates that while overweight people frequently drop about a fifth of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"People buying such medications need to be cognizant of the risk of fast rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting weight within about one and a half years.
Analyzing Treatments
The analysis, which looked at dozens of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with older methods.
Scientists emphasize that people who shed pounds through dieting usually see a more gradual creep back—around 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Nutrition scientists believe the way of the jabs accounts for the amplified rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement leads to appetite is no longer kept in check, making overeating a significant risk."
A Chronic Disease?
Health authorities recommend the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts contend that, given the high risk of relapse, the treatment is often long-term.
This perspective is echoed by drug manufacturers, who say that the findings "emphasize the long-term character of excess weight," similar to managing conditions like diabetes.
Patient Accounts
Individuals who have discontinued the medication explain a intense return of appetite.
"It was like a switch that goes on and you become ravenous," said a patient.
The struggle is exacerbated if users have not established lasting lifestyle or habit changes during treatment.
Significant Use
Survey data suggest that a significant number of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is more common among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while the jabs are effective agents for weight loss, they are not a standalone solution and long-term success hinges on integrated lifestyle management.
